Liver Diseases, AlcoholicP-TMS MetALDNCT07399600
Personalized Transcranial Magnetic Stimulation (TMS) for Metabolic Dysfunction and Alcohol-Related Liver Disease
A study testing Individually Targeted rTMS and Conventional rTMS in people with Liver Diseases, Alcoholic and Fatty Liver, run by The Affiliated Hospital of Hangzhou Normal University at 1 site in China.
Trial summary
The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, works to treat Metabolic dysfunction-associated and alcohol-associated liver disease (MetALD). Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Liver Diseases, Alcoholic, Fatty Liver, Metabolic Syndrome
- What is being tested?
- Individually Targeted rTMS and Conventional rTMS
- Type of treatment
- Medical device
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 105 participants
- Where
- 1 siteChina
- Study dates
- 1 Feb 2026to 31 Dec 2027
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Participants are able to understand the study protocol, requirements, and restrictions, are fully informed of potential adverse events, are willing to comply with follow-up visits, and voluntarily sign the informed consent form before enrollment.
- Meet the diagnostic criteria for MASLD according to the Guidelines for the Prevention and Treatment of Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition), and fulfill the European definition of MetALD with moderate alcohol consumption (20-50 g/day for women; 30-60 g/day for men).
- Age between 18 and 65 years.
- Body mass index (BMI) > 24 kg/m².
- No history of alcohol abuse.
Who cannot join
- Contraindications to magnetic resonance imaging (MRI) or transcranial magnetic stimulation (TMS).
- Mild cognitive impairment, defined as Montreal Cognitive Assessment (MoCA) score < 25.
- Severe comorbid somatic diseases or neurological disorders.
- History of psychiatric disorders, or current use of antipsychotic medications.
- Pregnant or breastfeeding women, or those planning pregnancy.
- Previous TMS treatment within the last 3 months.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
China1 site
The Affiliated Hospital of Hangzhou Normal University
Hangzhou, Zhejiang, 310015
junping shi, 86+13957121199, 20131004@hznu.edu.cn
About this study
Official title: Personalized Transcranial Magnetic Stimulation for Metabolic Dysfunction and Alcohol-Related Liver Disease (MetALD): A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, works to treat Metabolic dysfunction-associated and alcohol-associated liver disease (MetALD). The main questions it aims to answer are:
- Can rTMS effectively treat MetALD?
- Is an individualized, precision-targeted rTMS approach more effective than the standard rTMS method?
- What changes in brain activity are associated with the treatment?
Read more
Researchers will compare three different types of stimulation:
- Group A: Individualized rTMS targeting a deep brain reward area (the Nucleus Accumbens) based on each participant's brain scan (fMRI).
- Group B: Standard rTMS applied using the traditional "5 cm" rule for positioning.
- Group C: Sham (placebo) rTMS, which mimics the procedure but delivers no significant magnetic stimulation.
Participants will:
- Be randomly assigned to one of the three groups (A, B, or C).
- Undergo an MRI brain scan before starting treatment.
- Receive a total of 20 rTMS sessions, completing at least 4 sessions per week.
- Have additional MRI scans and clinical assessments halfway through and immediately after the treatment course.
- Attend follow-up visits at 1, 3, and 6 months after treatment completion to assess long-term effects.
- Conditions
- Liver Diseases, Alcoholic, Fatty Liver, Metabolic Syndrome
- Being tested
- Individually Targeted rTMS, Conventional rTMS, Transcranial Magnetic Stimulation Sham
- Keywords
- Liver Diseases, Alcoholic, Fatty Liver, Metabolic Syndrome, Transcranial Magnetic Stimulation, Randomized Controlled Trial
- Medical subject headings
- Liver Diseases, Alcoholic, Fatty Liver, Metabolic Syndrome
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Individually Targeted rTMSDevice
Participants will receive individualized transcranial magnetic stimulation (TMS) based on neuroimaging-guided localization of the nucleus accumbens (NAc). After the first MRI scan, participants will be randomized by an independent researcher responsible for data analysis. The individualized stimulation coordinates will be provided to the TMS operator before treatment.
Intervention will be delivered using intermittent theta-burst stimulation (iTBS): the coil will be placed tangentially to the scalp over the individualized target. Stimulation parameters: 90% resting motor threshold (RMT); bursts of 3 pulses at 50 Hz; bursts repeated at 5 Hz; a total of 1800 pulses per session; stimulation duration 570 seconds. Each participant will receive 20 sessions in total, with at least 2 treatment days per week (2 sessions/day, 4 sessions/week). MRI and clinical assessments will be repeated at mid-treatment and after treatment completion, with follow-up clinical evaluations at 1, 3, and 6 months.
Conventional rTMSDevice
Conventional rTMS is applied to the left dorsolateral prefrontal cortex (DLPFC) using the standard 5 cm rule for scalp-based localization. Stimulation is delivered with intermittent theta-burst stimulation (iTBS) at 90% resting motor threshold (RMT), 3 pulses at 50 Hz per burst, repeated at 5 Hz, for a total of 1800 pulses per session. Each session lasts about 570 seconds. Participants complete 20 sessions over 4 weeks, with 2 sessions per day on 2 days per week.
Transcranial Magnetic Stimulation ShamDevice
Sham rTMS is delivered using a sham coil or low-intensity stimulation (10% RMT) to mimic the clicking sounds and scalp sensations of active rTMS without producing cortical activation. The sham sessions are matched to the active treatment in frequency, duration, and total number: 20 sessions in 4 weeks (2 sessions/day, 2 days/week, 570 seconds per session).
| Study group | Role | What they receive |
|---|---|---|
| Conventional rTMS | Active comparator | Not described Receives: Device: Conventional rTMS |
| Sham rTMS | Sham comparator | Not described Receives: Device: Transcranial Magnetic Stimulation Sham |
| Active rTMS | Experimental | Not described Receives: Device: Individually Targeted rTMS |
What is being measured
The primary outcome is the main question the study is designed to answer.
Percent Change in Liver Fat Content (LFC) From Baseline to End of Treatment as Measured by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF)
Measured: From baseline to the end of treatment (Week 4)
Secondary outcomes (29)
Change in Controlled Attenuation Parameter (CAP, dB/m) From Baseline as Assessed by Vibration-Controlled Transient Elastography (FibroScan® VCTE)
Measured: From baseline to mid-treatment (Week 2), end of treatment (Week 4), and at 1-, 3-, and 6-month follow-up
Change in Liver Stiffness Measurement (LSM, kPa) From Baseline as Assessed by FibroScan® VCTE
Measured: From baseline to mid-treatment (Week 2), end of treatment (Week 4), and at 1-, 3-, and 6-month follow-up
LFC From Baseline as Measured by MRI-PDFF
Measured: From baseline to the end of treatment (Week 4)
Proportion of Participants Achieving ≥30% or ≥50% Reduction in LFC From Baseline
Measured: From baseline to the end of treatment (Week 4)
Change in Serum Levels of Liver Enzymes (ALT, AST, ALP, GGT [U/L]) From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Level of Albumin From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in International Normalized Ratio (INR) From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Prothrombin Time (PT) From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Level of Total Bilirubin (TBIL) From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Proportion of Participants With ALT Reduction >17 U/L From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Glucose Metabolism Markers (HOMA-IR [Index]; HOMA-β [Index]) From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Glucose Metabolism Markers (HbA1c [%]) From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Fasting Plasma Glucose (FPG) From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Fasting Insulin From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Concentration of Conventional Lipid Panel (TC, TG, HDL-C, LDL-C, non-HDL-C, VLDL-C [mmol/L]) From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Concentration of Apolipoproteins (Apo A1, Apo B [g/L]) From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Lipoprotein(a) (Lp(a)) Concentration From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Free Fatty Acids (FFA) Concentration From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Body Weight [kg] From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in BMI [kg/m²] From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Body Circumferences (Waist, Hip) [cm] From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Waist-to-Hip Ratio From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in General Food Craving Questionnaire-Trait (G-FCQ-T) Total Score From Baseline
G-FCQ-T The General Food Craving Questionnaire-Trait (G-FCQ-T) is a self-reported instrument used to assess the general tendency to experience food cravings. It comprises 21 items. Participants rate each item on a 6-point Likert scale ranging from 1 ("Never") to 6 ("Always"). The total score is the sum of all item ratings, with a possible range from 21 to 126. A higher total score indicates a more severe trait propensity for food craving.
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in General Food Craving Questionnaire-State (G-FCQ-S) Total Score From Baseline
G-FCQ-S The General Food Craving Questionnaire-State (G-FCQ-S) is a self-reported instrument used to assess the current, momentary state of food craving. It comprises 15 items. Participants rate each item on a 6-point Likert scale ranging from 1 ("Strongly Disagree") to 6 ("Strongly Agree"). The total score is the sum of all item ratings, with a possible range from 15 to 90. A higher total score indicates a more intense current state of food craving.
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Score on Visual Analogue Scale (VAS) for Subjective Food Craving From Baseline
Subjective food craving is assessed using a Visual Analogue Scale (VAS). Participants indicate their current, momentary level of food craving by marking a point on a 100-mm horizontal line. The left endpoint (0 mm) is labeled "No food craving at all," and the right endpoint (100 mm) is labeled "The most intense food craving imaginable." The score is determined by measuring the distance from the left endpoint to the participant's mark, ranging from 0 to 100. A higher score indicates a more intense subjective feeling of food craving.
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Caloric intake recorded by the Mint Health App From Baseline
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Alcohol Use Disorders Identification Test (AUDIT) Score From Baseline
The Alcohol Use Disorders Identification Test (AUDIT) is a simple, self-reported screening tool developed by the World Health Organization (WHO) to identify hazardous and harmful patterns of alcohol consumption. The questionnaire consists of 10 items. The first 8 items are scored on a scale from 0 to 4. Items 9 and 10 are scored 0, 2, or 4. The total score is the sum of all item ratings, with a possible range from 0 to 40. A higher total score indicates a greater likelihood of hazardous and harmful alcohol use, as well as possible alcohol dependence.
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Penn Alcohol Craving Scale (PACS) Score From Baseline
The Penn Alcohol Craving Scale (PACS) is a self-reported questionnaire designed to measure the intensity of an individual's craving for alcohol over the past week. The scale consists of 5 items assessing the frequency, duration, and intensity of craving, the ability to resist drinking, and the overall rating of craving. Each item is rated on a 6-point scale from 0 to 6, with varying verbal anchors for each item (e.g., "Never" to "Nearly All the Time"). The total score is the sum of all 5 item ratings, with a possible range from 0 to 30. A higher total score indicates a more severe level of subjective alcohol craving.
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Alcohol Consumption Assessed by the Timeline Followback (TLFB) Method From Baseline
Alcohol consumption is assessed using the Timeline Followback (TLFB) method, a structured interview that provides a quantitative estimate of an individual's daily drinking. Using a calendar to aid recall, participants retrospectively report their daily alcohol consumption over a specified period (e.g., the past 30 days). The data is used to calculate key metrics such as the number of drinking days, the number of heavy drinking days, and the average number of standard drinks consumed per day or per week. A higher value indicates a greater level of alcohol consumption.
Measured: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted10 Feb 2026
- Study start1 Feb 2026 (estimated)
- Primary completion31 Aug 2027 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Liver Diseases, AlcoholicStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 105 participants (estimated)
Sponsor and investigators
- Lead sponsor
- The Affiliated Hospital of Hangzhou Normal University
- Sponsor type
- University, hospital or other
- Responsible party
- Sponsor
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07399600
- Sponsor's protocol ID
- SJP20250926
- Acronym
- P-TMS MetALD
- Status last verified
- Jan 2026
- First submitted
- 17 Nov 2025
- Last updated
- 10 Feb 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 10 Feb 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Personalized Transcranial Magnetic Stimulation for Metabolic Dysfunction and Alcohol-Related Liver Disease (MetALD): A Prospective, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- ClinicalTrials.gov ID
- NCT07399600
- Acronym / sponsor ID
- P-TMS MetALD / SJP20250926
- Conditions
- Liver Diseases, Alcoholic, Fatty Liver, Metabolic Syndrome
- Keywords
- Liver Diseases, Alcoholic, Fatty Liver, Metabolic Syndrome, Transcranial Magnetic Stimulation, Randomized Controlled Trial
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 105 participants (estimated)
- Lead sponsor
- The Affiliated Hospital of Hangzhou Normal UniversityUniversity, hospital or other
- Study start
- 1 Feb 2026 (estimated)
- Primary completion
- 31 Aug 2027 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 10 Feb 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The goal of this clinical trial is to learn if repetitive Transcranial Magnetic Stimulation (rTMS), a non-invasive brain stimulation technique, works to treat Metabolic dysfunction-associated and alcohol-associated liver disease (MetALD). The main questions it aims to answer are:
- Can rTMS effectively treat MetALD?
- Is an individualized, precision-targeted rTMS approach more effective than the standard rTMS method?
- What changes in brain activity are associated with the treatment?
Researchers will compare three different types of stimulation:
- Group A: Individualized rTMS targeting a deep brain reward area (the Nucleus Accumbens) based on each participant's brain scan (fMRI).
- Group B: Standard rTMS applied using the traditional "5 cm" rule for positioning.
- Group C: Sham (placebo) rTMS, which mimics the procedure but delivers no significant magnetic stimulation.
Participants will:
- Be randomly assigned to one of the three groups (A, B, or C).
- Undergo an MRI brain scan before starting treatment.
- Receive a total of 20 rTMS sessions, completing at least 4 sessions per week.
- Have additional MRI scans and clinical assessments halfway through and immediately after the treatment course.
- Attend follow-up visits at 1, 3, and 6 months after treatment completion to assess long-term effects.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Conventional rTMS | Active comparator | Device: Conventional rTMS |
| Sham rTMS | Sham comparator | Device: Transcranial Magnetic Stimulation Sham |
| Active rTMS | Experimental | Device: Individually Targeted rTMS |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (5 listed)
- Participants are able to understand the study protocol, requirements, and restrictions, are fully informed of potential adverse events, are willing to comply with follow-up visits, and voluntarily sign the informed consent form before enrollment.
- Meet the diagnostic criteria for MASLD according to the Guidelines for the Prevention and Treatment of Metabolic (Non-Alcoholic) Fatty Liver Disease (2024 Edition), and fulfill the European definition of MetALD with moderate alcohol consumption (20-50 g/day for women; 30-60 g/day for men).
- Age between 18 and 65 years.
- Body mass index (BMI) > 24 kg/m².
- No history of alcohol abuse.
Key exclusion criteria (6 listed)
- Contraindications to magnetic resonance imaging (MRI) or transcranial magnetic stimulation (TMS).
- Mild cognitive impairment, defined as Montreal Cognitive Assessment (MoCA) score < 25.
- Severe comorbid somatic diseases or neurological disorders.
- History of psychiatric disorders, or current use of antipsychotic medications.
- Pregnant or breastfeeding women, or those planning pregnancy.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Individually Targeted rTMSParticipants will receive individualized transcranial magnetic stimulation (TMS) based on neuroimaging-guided localization of the nucleus accumbens (NAc). After the first MRI scan, participants will be randomized by an independent researcher responsible for data analysis. The individualized stimulation coordinates will be provided to the TMS operator before treatment. Intervention will be delivered using intermittent theta-burst stimulation (iTBS): the coil will be placed tangentially to the scalp over the individualized target. Stimulation parameters: 90% resting motor threshold (RMT); bursts of 3 pulses at 50 Hz; bursts repeated at 5 Hz; a total of 1800 pulses per session; stimulation duration 570 seconds. Each participant will receive 20 sessions in total, with at least 2 treatment days per week (2 sessions/day, 4 sessions/week). MRI and clinical assessments will be repeated at mid-treatment and after treatment completion, with follow-up clinical evaluations at 1, 3, and 6 months. | Device | Active rTMS |
| Conventional rTMSConventional rTMS is applied to the left dorsolateral prefrontal cortex (DLPFC) using the standard 5 cm rule for scalp-based localization. Stimulation is delivered with intermittent theta-burst stimulation (iTBS) at 90% resting motor threshold (RMT), 3 pulses at 50 Hz per burst, repeated at 5 Hz, for a total of 1800 pulses per session. Each session lasts about 570 seconds. Participants complete 20 sessions over 4 weeks, with 2 sessions per day on 2 days per week. | Device | Conventional rTMS |
| Transcranial Magnetic Stimulation ShamSham rTMS is delivered using a sham coil or low-intensity stimulation (10% RMT) to mimic the clicking sounds and scalp sensations of active rTMS without producing cortical activation. The sham sessions are matched to the active treatment in frequency, duration, and total number: 20 sessions in 4 weeks (2 sessions/day, 2 days/week, 570 seconds per session). | Device | Sham rTMS |
Primary outcome
Percent Change in Liver Fat Content (LFC) From Baseline to End of Treatment as Measured by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF)
Time frame: From baseline to the end of treatment (Week 4)
29 secondary outcomes
Change in Controlled Attenuation Parameter (CAP, dB/m) From Baseline as Assessed by Vibration-Controlled Transient Elastography (FibroScan® VCTE)
Time frame: From baseline to mid-treatment (Week 2), end of treatment (Week 4), and at 1-, 3-, and 6-month follow-up
Change in Liver Stiffness Measurement (LSM, kPa) From Baseline as Assessed by FibroScan® VCTE
Time frame: From baseline to mid-treatment (Week 2), end of treatment (Week 4), and at 1-, 3-, and 6-month follow-up
LFC From Baseline as Measured by MRI-PDFF
Time frame: From baseline to the end of treatment (Week 4)
Proportion of Participants Achieving ≥30% or ≥50% Reduction in LFC From Baseline
Time frame: From baseline to the end of treatment (Week 4)
Change in Serum Levels of Liver Enzymes (ALT, AST, ALP, GGT [U/L]) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Level of Albumin From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in International Normalized Ratio (INR) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Prothrombin Time (PT) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Level of Total Bilirubin (TBIL) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Proportion of Participants With ALT Reduction >17 U/L From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Glucose Metabolism Markers (HOMA-IR [Index]; HOMA-β [Index]) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Glucose Metabolism Markers (HbA1c [%]) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Fasting Plasma Glucose (FPG) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Fasting Insulin From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Concentration of Conventional Lipid Panel (TC, TG, HDL-C, LDL-C, non-HDL-C, VLDL-C [mmol/L]) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Concentration of Apolipoproteins (Apo A1, Apo B [g/L]) From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Lipoprotein(a) (Lp(a)) Concentration From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Serum Free Fatty Acids (FFA) Concentration From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Body Weight [kg] From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in BMI [kg/m²] From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Body Circumferences (Waist, Hip) [cm] From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Waist-to-Hip Ratio From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in General Food Craving Questionnaire-Trait (G-FCQ-T) Total Score From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in General Food Craving Questionnaire-State (G-FCQ-S) Total Score From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Score on Visual Analogue Scale (VAS) for Subjective Food Craving From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Caloric intake recorded by the Mint Health App From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Alcohol Use Disorders Identification Test (AUDIT) Score From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Penn Alcohol Craving Scale (PACS) Score From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Change in Alcohol Consumption Assessed by the Timeline Followback (TLFB) Method From Baseline
Time frame: baseline, mid-treatment (Week 2), end of treatment (Week 4), 1, 3, 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 10 Feb 2026.
Related trials for Liver Diseases, Alcoholic
Not yet recruiting
Efficacy of Carnitine Complex in Improving Hepatic Steatosis in Potential Liver Donors
Hepatic Steatosis, Fatty Liver
Recruiting
NAFLD Clinical Care Pathway
NAFLD, MASLD
RecruitingPhase 3
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Metabolic Dysfunction-Associated Steatotic Liver Disease, MASLD
RecruitingPhase 1
A Study of Efimosfermin Alfa in Adults With Hepatic Impairment
Non-alcoholic Fatty Liver Disease
RecruitingPhase 2
A Study to Investigate the Safety and Efficacy of Efimosfermin Alfa Compared With Placebo in Adult Participants With Alcohol-related Liver Disease (ALD)
Liver Diseases, Alcoholic
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Individually Targeted rTMS and Conventional rTMS in people with Liver Diseases, Alcoholic and Fatty Liver, run by The Affiliated Hospital of Hangzhou Normal University at 1 site in China.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 5 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 10 Feb 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Junping Shi (+86 13957121199, 20131004@hznu.edu.cn), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Percent Change in Liver Fat Content (LFC) From Baseline to End of Treatment as Measured by Magnetic Resonance Imaging-Proton Density Fat Fraction (MRI-PDFF) (time frame: From baseline to the end of treatment (Week 4)). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 10 Feb 2026.